These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 30591082)

  • 1. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
    Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
    J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative clinical and molecular characterization of translocation renal cell carcinoma.
    Bakouny Z; Sadagopan A; Ravi P; Metaferia NY; Li J; AbuHammad S; Tang S; Denize T; Garner ER; Gao X; Braun DA; Hirsch L; Steinharter JA; Bouchard G; Walton E; West D; Labaki C; Dudani S; Gan CL; Sethunath V; Carvalho FLF; Imamovic A; Ricker C; Vokes NI; Nyman J; Berchuck JE; Park J; Hirsch MS; Haq R; Mary Lee GS; McGregor BA; Chang SL; Feldman AS; Wu CJ; McDermott DF; Heng DYC; Signoretti S; Van Allen EM; Choueiri TK; Viswanathan SR
    Cell Rep; 2022 Jan; 38(1):110190. PubMed ID: 34986355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
    Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
    Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
    Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathological characteristics of renal cell carcinomas with MiTF translocation.
    Filler T; Verkarre V; Peyrottes A; Poinard F; Lupo A; Dariane C; Hurel S; Timsit MO; Mejean A; Audenet F
    Fr J Urol; 2024 Mar; 34(2):102569. PubMed ID: 38717457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma.
    Zhao J; Tang Y; Hu X; Yin X; Chen Y; Chen J; Liu H; Liu H; Liang J; Zhang X; Zhao J; Zhu S; Ni Y; Wang Z; Dai J; Wang Z; Zhang Y; Yao J; Chen N; Shen P; Liu ZH; Zeng H; Sun GX
    Mol Cancer; 2024 Jun; 23(1):132. PubMed ID: 38926757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
    Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
    Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
    Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
    Geller JI; Argani P; Adeniran A; Hampton E; De Marzo A; Hicks J; Collins MH
    Cancer; 2008 Apr; 112(7):1607-16. PubMed ID: 18278810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
    Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
    Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
    Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
    Thouvenin J; Alhalabi O; Carlo M; Carril-Ajuria L; Hirsch L; Martinez-Chanza N; Négrier S; Campedel L; Martini D; Borchiellini D; Chahoud J; Lodi M; Barthélémy P; Hasanov E; Hahn AW; Gil T; Viswanathan SR; Bakouny Z; Msaouel P; Asim Bilen M; Choueiri TK; Albiges L; Tannir NM; Malouf GG
    Oncologist; 2022 Dec; 27(12):1041-1047. PubMed ID: 35979929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family.
    Ramphal R; Pappo A; Zielenska M; Grant R; Ngan BY
    Am J Clin Pathol; 2006 Sep; 126(3):349-64. PubMed ID: 16880148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
    Lang M; Vocke CD; Ricketts CJ; Metwalli AR; Ball MW; Schmidt LS; Linehan WM
    Urology; 2021 Mar; 149():89-97. PubMed ID: 33242557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
    Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.